Andreas Knudsen

Andreas Knudsen

Auto-generated profile, based on publicly available information

Andreas Knudsen

Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2014 in Journal of Nuclear Cardiology
Verified
Journal Article
Open access
PDF file
AKAndreas Knudsen
Andreas Knudsen
AHAnne Mette Fisker Hag
Anne Mette Fisker Hag
ALAnnika Loft
Annika Loft
EBEric von Benzon
Eric von Benzon
SKSune H. Keller
Sune H. Keller
Andreas KjaerAndreas Kjaer
Andreas Kjaer
HIV-infected patients are at increased risk of myocardial infarction and arterial inflammation has been suggested as a pathophysiological explanation. We compared the uptake of 18F-fluorodeoxyglucose (FDG) by PET in four arterial regions, and factors associated with FDG uptake in well-treated HIV-infected patients without cardiovascular disease (CVD) and healthy controls.

15 May 2014 in AIDS
Verified
Journal Article
Open access
AKAndreas Knudsen
Andreas Knudsen
TKTerese Lea Katzenstein
Terese Lea Katzenstein
TBThomas Benfield
Thomas Benfield
NJNiklas Rye Jørgensen
Niklas Rye Jørgensen
GKGitte Kronborg
Gitte Kronborg
ALAnne-Mette Lebech
Anne-Mette Lebech
Biomarkers of endothelial dysfunction, inflammation and coagulation are associated with atherosclerosis and cardiovascular disease, but their association and possible predictive value remain controversial among HIV-1-infected individuals. We sought to investigate the association of seven biomarkers with first-time myocardial infarction (MI) in an HIV-1-infected population. A matched case-control study of 54 cases and 54 controls. We compared 54 HIV-1-infected patients with verified first-time MI and 54 HIV-1-infected controls matched for age, duration of antiretroviral therapy, sex, smoking and no known cardiovascular disease. Levels of high-sensitivity C-reactive protein, soluble endothelial selectin, soluble vascular cell adhesion molecule, soluble intercellular adhesion molecule, matrix metalloprotease 9, myeloperoxidase, and plasminogen activator inhibitor 1 (PAI-1) were measured using a Luminex assay in plasma samples from routine visits both 12 and 2 months prior to the case patient's MI. The two groups had similar HIV characteristics and traditional cardiovascular risk factors. In univariate analysis, PAI-1 levels were associated with MI, whereas none of the other markers showed any association.In multivariate analyses adjusting for the D:A:D risk score, HIV viral load and high-sensitivity C-reactive protein, PAI-1 levels in the highest quartile were associated with a six to seven-fold increased risk of MI in both samples. High levels of PAI-1 were associated with risk of first-time MI in HIV-1-infected individuals independently of cardiovascular risk factors, HIV parameters and antiretroviral therapy. Therefore PAI-1 may be used for risk stratification and prediction of CHD, but further studies are needed.

14 September 2015 in HIV Medicine
Verified
Journal Article
Open access
PDF file
LRLine Jee Hartmann Rasmussen
Line Jee Hartmann Rasmussen
AKA Knudsen
A Knudsen
TKTl Katzenstein
Tl Katzenstein
JGJ Gerstoft
J Gerstoft
NON Obel
N Obel
ALAnne-Mette Lebech
Anne-Mette Lebech
Objectives: Patients infected with HIV are at increased risk of myocardial infarction (MI). Increased plasma levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) have been associated with increased risk of cardiovascular diseases (CVD), including MI in the general population. We tested suPAR as a predictive biomarker of MI in HIV‐1‐infected individuals.Methods: suPAR levels were investigated in a nested case‐control study of 55 HIV‐1‐infected cases with verified first‐time MI and 182 HIV‐1‐infected controls with no known CVD. Controls were matched for age, gender, duration of antiretroviral therapy (ART), smoking and no known CVD. suPAR was measured in the four plasma samples available for each patient at different time‐points; 1, Before initiation of ART; 2, 3 months after initiation of ART; 3, 1 year before the case's MI; and 4, The last sample available before the case's MI.Results: In unadjusted conditional regression analysis, higher levels of suPAR were associated with a significant increase in risk of MI at all time‐points. Patients in the third and fourth suPAR quartiles had a three‐ to 10‐fold higher risk of MI compared to patients in the lowest suPAR quartile at all time‐points. suPAR remained a strong significant predictor of MI, when adjusting for HIV‐1 RNA, total cholesterol, triglycerides and high‐density lipoprotein.Conclusion: Elevated suPAR levels were associated with increased risk of MI in HIV‐infected patients, suggesting that suPAR could be a useful biomarker for prediction of first‐time MI in this patient group, even years before the event.

21 May 2013 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AKAndreas Knudsen
Andreas Knudsen
HMHolger Jon Møller
Holger Jon Møller
TKTerese Lea Katzenstein
Terese Lea Katzenstein
JGJan Gerstoft
Jan Gerstoft
NONiels Obel
Niels Obel
ALAnne-Mette Lebech
Anne-Mette Lebech
Soluble CD163 (sCD163) has been associated with arterial inflammation and non-calcified plaques in human immunodeficiency virus (HIV)-infected individuals and has therefore been suggested as a predictive biomarker of myocardial infarction (MI). We conducted a nested case–control study of 55 cases with first-time MI and 182 controls matched for age, duration of antiretroviral therapy (ART), gender, smoking, and no known cardiovascular disease. All patients had four available plasma samples, 1: Before initiation of antiretroviral therapy (ART), 2: Three months after ART, 3: One year before the case’s MI, and 4: The last sample available before the case’s MI. We used conditional logistic regression to estimate the association of sCD163 with first-time MI. The two groups had similar HIV-parameters and cardiovascular risk factors were equally distributed. There was no significant association between sCD163 and MI neither in samples obtained one year before (OR 1.05, CI 95% 0.85 – 1.29, p = 0.66) nor two months before (OR 1.20, CI 95% 0.98-1.47 p = 0.08). sCD163 did not prove to be a useful biomarker for prediction of first-time MI in a HIV-infected population.

1 October 2015 in Medicine
Verified
Journal Article
Open access
AKAndreas Knudsen
Andreas Knudsen
TCThomas E. Christensen
Thomas E. Christensen
AGAdam Ali Ghotbi
Adam Ali Ghotbi
PHPhilip Hasbak
Philip Hasbak
ALAnne-Mette Lebech
Anne-Mette Lebech
RRRasmus Sejersten Ripa
Rasmus Sejersten Ripa
Studies have found HIV-infected patients to be at increased risk of myocardial infarction, which may be caused by coronary microvascular dysfunction. For the first time among HIV-infected patients, we assessed the myocardial flow reserve (MFR) by Rubidium-82 (82Rb) positron emission tomography (PET), which can quantify the coronary microvascular function. MFR has proved highly predictive of future coronary artery disease and cardiovascular events in the general population.In a prospective cross-sectional study, HIV-infected patients all receiving antiretroviral therapy (ART) with full viral suppression and HIV-uninfected controls were scanned using 82Rb PET/computed tomography at rest and adenosine-induced stress, thereby obtaining the MFR (stress flow/rest flow), stratified into low ≤1.5, borderline >1.5 to 2.0, or normal >2.0.Fifty-six HIV-infected patients and 25 controls were included. The HIV-infected patients had a mean age of 53 years (range 37-68 years) with 23% active smokers. The controls had a mean age of 52 years (range 36-68 years) and 26% active smokers. In the HIV-infected group 73% had a normal MFR, 17% borderline, and 10% low values of MFR. Among controls these values were 71%, 19%, and 10%, respectively (P = 0.99). However, the HIV-infected group had lower values of stress myocardial blood flow (MBF) (2.63 ± 0.09 mL/g/min vs 2.99 ± 0.14 mL/g/min; P = 0.03). We found no evidence of decreased MFR as assessed by 82Rb PET among HIV-infected patients on stable ART with full viral suppression compared with HIV-uninfected controls. We did notice a decreased MBF during stress.

1 September 2018 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
AKAndreas Knudsen
Andreas Knudsen
KTKristina Thorsteinsson
Kristina Thorsteinsson
TCThomas E Christensen
Thomas E Christensen
PHPhilip Hasbak
Philip Hasbak
RRRasmus Sejersten Ripa
Rasmus Sejersten Ripa
Andreas KjaerAndreas Kjaer
Andreas Kjaer
People living with HIV (PLWH) appear to be at increased risk of cardiovascular disease (CVD), and this is possibly more pronounced in women living with HIV (WLWH). In the general population, men are more likely to develop obstructive coronary artery disease (CAD), and women often present with a nonobstructive pattern with cardiac microvascular dysfunction. We investigated cardiac microvascular function in men and women living with HIV and tested for association with cytomegalovirus (CMV) immunoglobulin G (IgG), as this has been associated with CVD in PLWH. In a cross-sectional study, 94 PLWH on antiretroviral therapy were scanned with 82Rb positron emission tomography/computed tomography at rest and during adenosine-induced stress, which enables the quantification of the myocardial flow reserve (MFR). CMV IgG was measured in plasma. WLWH had significantly lower MFR compared with men living with HIV (MLWH; P = .003), and >45% of the women had an MFR indicative of cardiac microvascular dysfunction, whereas this was only true for 24% of men (P = .03). CMV IgG concentrations were inversely associated with MFR among WLWH but not MLWH (P = .05 for interaction). In this first study comparing MFR in women and men living with HIV, we found that WLWH had significantly lower MFR than MLWH and 45% of the women had cardiac microvascular dysfunction despite younger age and lower cardiovascular risk. Furthermore, CMV IgG was inversely associated with MFR among women but not men. This calls for attention to CVD among young WLWH even with low cardiovascular risk.